Literature DB >> 12620807

Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.

Peter J King1, Deborah J Lee, Ryan A Reinke, Joseph G Victoria, Keola Beale, W Edward Robinson.   

Abstract

L-chicoric acid (L-CA) is a potent inhibitor of HIV integrase (IN) in vitro. In this report, the effects of a glycine to serine mutation at position 140 (G140S) on HIV IN and its effects on IN inhibitor resistance are described. HIV containing the G140S mutation showed a delay in replication. Using real-time polymerase chain reaction, the delay was secondary to a failure in integration. The mutant protein (IN(G140S)) was attenuated approximately four-fold for catalysis under equilibrium conditions compared to wild-type IN (IN(WT)) and attenuated five-fold in steady-state kinetic analysis of disintegration. Fifty percent inhibitory concentration assays were performed with IN inhibitors against both IN proteins in disintegration and strand transfer reactions. IN(G140S) was resistant to both L-CA and L-731,988, a diketoacid. HIV containing the mutation was resistant to both inhibitors as well. The G140S mutation attenuates IN activity and confers resistance to IN inhibitors, suggesting that diketoacids and L-CA interact with a similar binding site on HIV IN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620807     DOI: 10.1016/s0042-6822(02)00042-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

Authors:  Mathieu Métifiot; Kasthuraiah Maddali; Alena Naumova; Xuemin Zhang; Christophe Marchand; Yves Pommier
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

2.  Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.

Authors:  Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.

Authors:  Zixin Hu; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

4.  Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.

Authors:  Valery Fikkert; Bénédicte Van Maele; Jo Vercammen; Anke Hantson; Barbara Van Remoortel; Martine Michiels; Cristina Gurnari; Christophe Pannecouque; Marc De Maeyer; Yves Engelborghs; Erik De Clercq; Zeger Debyser; Myriam Witvrouw
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.

Authors:  Nick Shkriabai; Sachindra S Patil; Sonja Hess; Scott R Budihas; Robert Craigie; Terrence R Burke; Stuart F J Le Grice; Mamuka Kvaratskhelia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.

Authors:  Deborah J Lee; W E Robinson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Authors:  Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.

Authors:  Isabelle Malet; Olivier Delelis; Marc-Antoine Valantin; Brigitte Montes; Cathia Soulie; Marc Wirden; Luba Tchertanov; Gilles Peytavin; Jacques Reynes; Jean-François Mouscadet; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

9.  Resistance to integrase inhibitors.

Authors:  Mathieu Métifiot; Christophe Marchand; Kasthuraiah Maddali; Yves Pommier
Journal:  Viruses       Date:  2010-06-25       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.